Publications by authors named "L I Sly"
Article Synopsis
- This text discusses the treatment of arthritis using conventional medications like corticosteroids and methotrexate, which have significant side effects and costs, while introducing البوليمر المناعي (polyvalent immunoglobulins) as a less commonly used alternative derived from bovine colostrum.* -
- Two male patients with chronic arthritis unresponsive to standard treatments were administered oral polyvalent immunoglobulins, showing rapid pain relief and improvement in one patient’s blood cell count after discontinuing methotrexate.* -
- The results suggest that polyvalent immunoglobulins could effectively reduce inflammation markers and provide a viable treatment option for patients who struggle with traditional therapies.*
Lokivetmab (Cytopoint®, Zoetis) is a canine monoclonal antibody that specifically binds and neutralizes interleukin (IL)-31. Lokivetmab is approved for use in dogs for the treatment of atopic dermatitis (AD) and allergic dermatitis. The laboratory safety of lokivetmab was evaluated in 2 studies by adapting the science-based, case-by-case approach used for preclinical and early clinical safety evaluation of human biopharmaceuticals.
View Article and Find Full Text PDFAs an essential component of immunity, macrophages have key roles in mammalian host defense, tissue homeostasis, and repair, as well as in disease pathogenesis and pathophysiology. A source of fascination and extensive research, in this Opinion we challenge the utility of the M1-M2 paradigm, and discuss the importance of accurate characterization of human macrophages. We comment on the application of single cell analytics to define macrophage subpopulations and how this could advance therapeutic options.
View Article and Find Full Text PDFBackground: A female patient aged 49 years with a rectal adenocarcinoma underwent tumor resection and multiple follow-up surgical operations whilst receiving compassionate therapy with polyvalent immunoglobulins derived from bovine colostrum (KMP01), a potential modulator of the pro-tumor inflammatory response.
Aims: Assessment of safety of the treatment, effect on tumor recurrence, and effect on parameters associated with the pro-tumor inflammatory response.
Materials And Methods: The dose of KMP01 varied from 72 g daily in the perioperative period to 12 - 24 g daily thereafter.
Article Synopsis
- Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve chronic inflammation of the gastrointestinal tract, leading to significant immune cell infiltration and tissue damage.
- Current treatments range from traditional medications to biologics, with the latter, like anti-TNF therapies (e.g., infliximab), targeting specific inflammatory pathways, although up to 40% of patients may not respond.
- Newer biologics, such as vedolizumab, aim to reduce inflammation by targeting leukocyte trafficking without risking severe side effects, though the exact mechanisms of action of vedolizumab in blocking T-cell recruitment remain unclear.